BioCentury | Feb 15, 2017
Distillery Therapeutics

Other

...the OptiNose bidirectional nasal delivery device, in Phase II testing for autism. Novartis AG markets Syntocinon...
BioCentury | Jun 3, 2015
Company News

Management tracks

...it also is developing the drug to treat rage disorders in autism. Its pipeline includes Syntocinon...
BioCentury | Jan 13, 2014
Finance

Highlights of weekly biotech stock moves

...Last month, Novartis AG (NYSE:NVS; SIX:NOVN) granted Retrophin exclusive, U.S. rights to develop and commercialize Syntocinon...
BioCentury | Jan 11, 2014
Financial News

Retrophin raises $40M in follow-on, lists on NASDAQ

...up $2.99 (35%) to $10.49 on Friday Retrophin submitted an application to FDA to reintroduce Syntocinon...
...Last month, Novartis AG (NYSE:NVS; SIX:NOVN) granted Retrophin exclusive, U.S. rights to develop and commercialize Syntocinon...
...for commercial reasons in 1997. Novartis still markets the product in Europe and other countries. Syntocinon...
BioCentury | Dec 19, 2013
Financial News

Retrophin to raise $40 million, list on NASDAQ

...granted Retrophin exclusive, U.S. rights to develop and commercialize Syntocinon oxytocin nasal spray. Novartis discontinued Syntocinon...
BioCentury | Dec 16, 2013
Company News

Kyalin Biosciences, Retrophin, Novartis deal

...be reached for comment. Separately, Novartis granted Retrophin exclusive, U.S. rights to develop and commercialize Syntocinon...
...plans to reintroduce the product in the U.S. in 2Q14 and conduct clinical trials for Syntocinon...
...controlled studies to confirm findings of improvement in patients with schizophrenia and autism. Novartis discontinued Syntocinon...
Items per page:
1 - 6 of 6